Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Sparks

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
European Journal of Nuclear Medicine and Molecular Imaging|April 8, 2025
Safety and dosimetry of [<sup>177</sup>Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P studyMark N Gaze, Daria Handkiewicz-Junak, Raquel Hladun, et al.
Frontiers in Oncology|January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trialAaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
ACS Medicinal Chemistry Letters|May 20, 2017
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncologyEddy W Yue, Richard Sparks, Padmaja Polam, et al.
Journal of Medicinal Chemistry|October 14, 2005
Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimeticsAndrew P Combs, Eddy W Yue, Michael Bower, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination StrategiesMatthew C Stubbs, Timothy C Burn, Richard Sparks, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
European Journal of Nuclear Medicine and Molecular Imaging|April 8, 2025
Safety and dosimetry of [<sup>177</sup>Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P studyMark N Gaze, Daria Handkiewicz-Junak, Raquel Hladun, et al.
Frontiers in Oncology|January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trialAaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
ACS Medicinal Chemistry Letters|May 20, 2017
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncologyEddy W Yue, Richard Sparks, Padmaja Polam, et al.
Journal of Medicinal Chemistry|October 14, 2005
Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimeticsAndrew P Combs, Eddy W Yue, Michael Bower, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination StrategiesMatthew C Stubbs, Timothy C Burn, Richard Sparks, et al.
Pageof 2